Cannabis as a Gateway Drug for Opioid Use Disorder
- PMID: 32631185
- PMCID: PMC7359408
- DOI: 10.1177/1073110520935338
Cannabis as a Gateway Drug for Opioid Use Disorder
Abstract
Cannabis use in some individuals can meaningfully introduce de novo risk for the initiation of opioid use and development of opioid use disorder. These risks may be particularly high during adolescence when cannabis use may disrupt critical periods of neurodevelopment. Current research studying the combination of genetic and environmental factors involved in substance use disorders is poorly understood. More research is needed, particularly to identify which adolescents are most at risk and to develop effective interventions addressing contributing factors such as trauma and psychiatric comorbidity.
Comment in
-
Regulating Marijuana Use in the United States: Moving Past the Gateway Hypothesis of Drug Use.J Law Med Ethics. 2020 Jun;48(2):275-278. doi: 10.1177/1073110520935339. J Law Med Ethics. 2020. PMID: 32631178
References
-
- Williams AR, “Medical and Recreational Marijuana Policy: From Prohibition to the Rise of Regulation,” in Marijuana and Mental Health, ed. Compton M (Washington, DC: American Psychiatric Publishing Inc., 2016): 39–69;
- Williams AR, Olfson M, Kim JD, Martins SS, and Kleber HD, “Older, Less Regulated Medical Marijuana Programs Have Much Greater Enrollment Rates,” Health Affairs 35, no. 3 (2016):480–488. - PMC - PubMed
-
- Humphreys K and Saitz R, “Should Physicians Recommend Replacing Opioids with Cannabis?” JAMA 321, no. 7 (2019): 639–640. - PubMed
-
- Szalavitz M, “Once and for All, Marijuana is Not a Gateway Drug,” Vice News, October 13, 2015.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical